The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
Portfolio of 16 European Consumer Healthcare brands from Sanofi
Advising Sanofi, a leading global player in the Consumer Healthcare market, on the divestiture of a portfolio of 16 European Consumer Healthcare brands to STADA, a German pharmaceutical and consumer healthcare company owned by Bain Capital and Cinven
AtlasEdge Joint Venture
Advised Liberty Global Inc., one of the world’s leading converged telecommunication companies with operations in seven European countries, on the creation of AtlasEdge, a pan-European Edge Data Centre Joint Venture with the digital infrastructure investor Digital Colony
Whinstone Inc. – Subsidiary of Northern Data AG
Advising Northern Data AG, a Germany based developer and operator of high-performance computing (“HPC”) infrastructure solutions, on the sale of its U.S. subsidiary Whinstone Inc., an HPC data center operator based in Rockdale, Texas, to Riot Blockchain Inc., a U.S. based publicly-traded bitcoin miner
Alumisource Corporation
Advised Sims Limited, a global leader in metal recycling and electronics recovery, on the acquisition of certain commercial and operating assets of Alumisource Corporation
Learning Materials for the K-12 Segment in Spain
Advising Sanoma Oyj (HEL: SAA1V), a European learning and media company listed on Nasdaq Helsinki, on the acquisition of Santillana Spain, a leading Spanish provider of K-12 learning materials, from Promotora de Informaciones S.A. (Grupo Prisa, BME: PRS)
Axión Group
Advised AMP Capital on the sale of its portfolio company Axión Group, a leading independent broadcasting and telecommunications infrastructure provider in Spain, to Asterion Industrial Partners, a Spanish infrastructure fund
Cosmetic applications endolysin
Advised Micreos, a fast-growing biotechnology company, on a long-term license agreement with L’Oréal for one of Micreos’ phage-based active ingredients, SA.100
VX Fiber
Advised VX Fiber, an international infrastructure and technology business focused on Fibre-to-the-Home networks, on its sale to the infrastructure fund AMP Capital
Community Fibre Limited
Advised Warburg Pincus LLC and Deutsche Telekom Capital Partners on the acquisition of a majority stake in CommunityFibre Limited, a leading full fibre network infrastructure platform in UK
Centrifuge and processing equipment business of Koki Holdings Co., Ltd.
Advised Eppendorf AG, a leading family-owned life science company, on the acquisition of the centrifuge and processing equipment business of KKR-owned Koki Holdings Co., Ltd., a manufacturer of power tools and centrifuge and processing equipment
Formation of an incorporated joint venture
Advised Flinders Mines, an ASX-listed mining exploration and development company, on the formation of an incorporated joint venture with BBI Group, providing a structure for the potential integrated financing and development of Flinders’ Pilbara Iron Ore Project and BBI Group’s Balla Balla rail and port infrastructure project
Global rights (excluding North America) to ThermaCare (United Kingdom)
Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the global rights (excluding North America) for ThermaCare, including a dedicated manufacturing facility based in Albany, Georgia, USA, to Angelini Pharma
Wildstone
Advised Wildstone, a leading aggregation and digitalization company for outdoor billboards, on its sale to Digital Colony, whilst contemporaneously acquiring Insite Poster Group
FTTH network including 933,000 BU’s
Advising MasMovil, the fourth largest Spanish telecom operator, in the sale of part of its fibre-to-the-home (FTTH) network to an international infrastructure fund. The transaction perimeter includes 933,000 homes across 5 main Spanish cities
Kidman Resources Limited
Advised Kidman Resources, an ASX-listed hard rock lithium mining company, on its sale to Wesfarmers, one of Australia’s largest diversified listed companies
Starpharma Holdings Limited, patented VivaGel BV® product
Advised Starpharma Holdings Limited on a US licensing agreement of its patented VivaGel BV® product with ITF Pharma, a US subsidiary of Italfarmaco S.p.A., a privately held European specialty pharmaceutical company
Montserrat Day Hospital Group
Advised ASX-listed Primary Health Care, one of Australia’s leading providers of multi-disciplinary healthcare services, on its acquisition of the Montserrat Day Hospital Group, an owner and operator of day hospital facilities
Martabe gold and silver mine
Advised EMR Capital, a specialist resources private equity manager, on the sale of the Martabe gold and silver mine to United Tractors
IslaLink
Advised EQT, a leading alternative investments firm with more than EUR 37 billion of AUM on the sale of its portfolio company IslaLink, a leading neutral and independent submarine fiber infrastructure operator in the Balearic Islands
Novartis AG’s 36.5% stake in Consumer Health Joint Venture
Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture
MorphoSys AG
Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab
Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
US rights to an authorized generic version of Adderall XR
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR